Moreover, short acting substances, e.g. IL-1R-blockade with anakinra for which positive data exist from other neutrophilic hyperinflammatory conditions such as Still's disease with ARDS and septic shock deserves special consideration, as it allows the therapy to be quickly de-escalated 41,42. This evidence concerns the gene IL1R1 and systemic-onset juvenile idiopathic arthritis.